Goldman Sachs initiates coverage on Momenta Pharmaceuticals (NASDAQ: MNTA) with a Neutral rating and $15 12-month price target.

This article: 94 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE